APEX Tech Acquisition

This filing establishes the contractual trust, redemption, and liquidation mechanics for a new SPAC. Investors tracking redemption deadlines and trust value now have a baseline: trust is $10.00 per share, deadline is 15 months from the IPO effective date (likely late May 2027), and extensions require shareholder approval with redemption rights. Sponsor conduct terms are disclosed: sponsor shares cost ~$0.009 each, creating significant dilution and incentive to close any deal. The SPAC's team is overwhelmingly tied to China (CEO is based in China, all directors have significant PRC ties), and the prospectus extensively warns that CFIUS review could block a U.S. target acquisition and that PRC regulatory risks (CSRC filing, cybersecurity, data) could impair the SPAC's search. This is material for assessing sponsor/geopolitical risk.

For investors tracking the SEARCHING status, trust trajectory, and 2027-05-26 deadline, this absence of insider trading eliminates near-term speculation regarding sponsorship cash requirements, deal-validation accumulation, or exit positioning ahead of extension votes. The document contains no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel attributed to any chief executive, sponsor representative, or target operator. No numerical metrics beyond the zero-transaction declaration and the 2026-02-25 date (SEC sequence 0001477932-26-001043) appear in the text. Because it delivers no operational, valuation, or redemption-risk updates, it is non-material to immediate investor decisioning, confidence: 1.0

This filing confirms the structural parameters of APEX Tech Acquisition’s proposed initial public offering without introducing new business terms, target selections, or redemption mechanics. Regarding sponsor conduct and cap table economics, Item 15 of the document states that the sponsor originally agreed to purchase 1,725,000 founder shares for $25,000, but a January 2026 amendment retroactively increased the total holding to 2,875,000 shares for the identical $25,000 consideration (approximately $0.009 per share). The filing notes that up to 375,000 founder shares remain subject to forfeiture if the underwriters do not fully exercise their over-allotment option, ensuring the sponsor, executive officers, and independent director nominees will collectively beneficially own 20% of the post-offering capitalization. Concurrently, the sponsor has contractually committed to purchasing 197,000 private units at $10.00 per unit at consummation, with an obligation to buy up to 15,000 additional private units at $10.00 each if the over-allotment is triggered. The document contains no disclosures regarding an identified target, business combination timeline, trust account balance adjustments, redemption deadlines, extension votes, personnel changes, litigation, customer data, revenue forecasts, or strategic partnerships. All reported figures and terms reflect the registrant’s stated registration scope and pre-offering equity allocation.

These provisions directly anchor the public shareholder timeline and economic protections. The 15-month completion window dictates when mandatory extension votes or redemption rights activate, overriding calendar deadlines until effectiveness and trading commence. The dual-trust-deposit references ($60,000,000 versus $50,000,000/$57,500,000) require monitoring the final effective prospectus to confirm per-unit backing expectations, though both frameworks tie fund retention to public share count. The sponsor’s nominal founder share cost and $[2,008,000] private placement provide baseline liquidity, while explicit forfeiture clauses on founder shares and deferred underwriter shares remove financial upside if liquidation occurs, aligning insider/underwriter incentives toward deal execution rather than trust dissolution. The 80% fair market value floor in Section 7.7 establishes a hard minimum transaction scale relative to trust assets. Section 2.17’s explicit search-phase declaration signals zero near-term deSPAC catalysts, making future valuation purely dependent on management outreach, market conditions, and subsequent proxy filings. Investors should track the transition from this S-1/A to the effective prospectus, the Form 8-K audited balance sheet post-closing, and eventual notice periods for extension or redemption elections.

The S-1 provides the first comprehensive look at this SPAC's structure, sponsor economics, trust mechanics, and management. It establishes the baseline for future redemptions, trust value ($10.00 per share, per the filing), and the 15-month deadline. The heavy China ties introduce unique risks that may affect deal sourcing and ability to complete a U.S. target combination. No specific target is identified; the SPAC is in searching status.

This filing establishes the initial structure and mechanics of a new SPAC, including trust value ($10.00 per unit), redemption rights, extension provisions, and sponsor economics. Investors tracking redemptions and deal progress need to note the 15-month deadline (extendable with shareholder vote) and the sponsor's ability to contribute funds for extensions. The document also reveals significant sponsor conduct risks: the sponsor paid only $0.0145 per founder share, creating high dilution for public shareholders; the sponsor is controlled by a PRC resident, which may limit the pool of U.S. target companies and invite CFIUS review; and management has no prior SPAC experience. The risks associated with a potential PRC-based target are heavily emphasized.

What changed: Quarterly report on Form 10-Q for APEX Tech Acquisition Inc. (TRAD) for the quarter ended May 31, 2026. Trust account balance $115,658,787 ($10.06 per share), up from $0 at IPO close due to $658,787 interest earned. No business combination announced or target selected. Entered into Finder's Engagement Agreement with California Hedge Fund Inc. on March 15, 2026, paying $250,000 retainer; amended May 15, 2026 to increase retainer to $500,000 (fully paid) and success fee from $3.75M to $4.5M. Cash outside trust only $2,667 with working capital deficit of $14,351. Going concern disclosure repeated. Sponsor promissory note repaid. No insider trading arrangements adopted or terminated. Why it matters: Trust per share remains at $10.06 with deadline May 2027 (15 months from IPO effective date). SPAC is actively searching via paid finder with $4.5M success fee, indicating deal pursuit. Minimal working capital outside trust raises risk of needing sponsor working capital loans to fund operations until a deal closes. Finder fees could dilute trust if paid from trust (though agreement specifies cash success fee, likely from outside trust). No redemptions or extensions yet.

What changed: A routine compliance exhibit, specifically a Joint Filing Agreement filed to authorize a single collective submission under Rule 13d-1(k). The document reports no modifications to redemption deadlines, trust value per share, extension provisions, deal progress, or sponsor conduct. Feis Equities LLC and Managing Member Lawrence M. Feis confirm only that they have agreed to submit the Schedule 13G dated May 21, 2026, and any future amendments, on behalf of both parties. Why it matters: Because the agreement is strictly procedural, it does not alter SPAC mechanics, shareholder redemption windows, or capital trust status. Neither Feis Equities LLC nor Lawrence M. Feis make any assertions regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. The filing conveys no material operational developments or financing adjustments beyond standard regulatory coordination.

What changed: Schedule 13G beneficial ownership report. Routine compliance exhibit. Highbridge Capital Management, LLC filed this beneficial ownership report. It contains no figures, percentages, or transactional timestamps, and cites no information regarding redemption deadlines, trust account mechanics, extension procedures, target acquisition progress, or sponsor conduct. Why it matters: Institutional ownership filings monitor shareholder concentration and potential voting influence over any future business combination. Because the provided text supplies neither percentage holdings nor historical trade records, it does not shift operational timelines, liquidity parameters, or governance controls for the Trust.

What changed: Routine compliance exhibit (Schedule 13G beneficial ownership report). The Schedule 13G identifies Polar Asset Management Partners Inc. as a reporting holder. The provided text contains no information regarding the 2027-05-26 redemption deadline, the $10.06 trust/share amount, extension mechanisms, target deal progress, or sponsor conduct. Why it matters: According to the filing, Polar Asset Management Partners Inc. has submitted a statutory disclosure confirming beneficial ownership that triggers the applicable reporting threshold. Because the excerpt omits the exact percentage, acquisition date, purchase price, and stated investment purpose, it does not alter trust account dynamics, trigger redemption scrutiny, or indicate advancement toward a business combination. Claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel are entirely absent from this routine equity reporting document.

What changed: Schedule 13G beneficial ownership report (a routine compliance exhibit). The filing discloses that Decagon Asset Management LLP and Benjamin John Durham have reported their aggregate stake in TRAD. The excerpt provides no share quantities, acquisition dates, or percentage thresholds. It contains no updates regarding redemption deadlines, trust value per share, extension proposals, business combination negotiations, or sponsor conduct. Consequently, there are no structural, timeline, or trust mechanics altered by this submission. Why it matters: This 13G confirms institutional capital attribution without advancing the target search, altering redemption windows, or changing trust distribution mechanics. Because the filing text attributes no statements to any executive, director, or advisor, it contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Investors tracking capital concentration and sponsorship alignment should await subsequent amendments or Schedule 13D filings, which would be required if the holders cross additional voting thresholds, acquire control, or intend to influence corporate governance—actions that would materially affect deal progress timing, potential bridge financing, or sponsor conduct oversight.

What changed: A Schedule 13G—beneficial ownership report filed by UBS Group AG. The filing attributes only standard institutional shareholding data to UBS Group AG. It reports no modifications to redemption deadlines, trust value per share, extension mechanisms, deal progress, or sponsor conduct. Why it matters: As a routine compliance exhibit tracking institutional ownership, the document does not mechanically affect the SPAC’s search window or shareholder redemption economics. The filing makes no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, leaving the SPAC’s operational parameters and capital structure unaddressed by this submission.

What changed: A Form 8-K current report filed by APEX Tech Acquisition Inc. disclosing the closing of the underwriters' over-allotment option and a concurrent private placement of additional units. According to the filing, on April 15, 2026, the underwriters fully exercised their 45-day over-allotment option to purchase an additional 302,869 Units at $10.00 per Unit, adding $3,028,690 in gross proceeds to the 11,197,131 units originally sold on February 27, 2026. Simultaneously, APEX INNOVATION ACQUISITION CORP. purchased 3,029 Private Placement Units at $10.00 per unit for $30,285. Per the unaudited pro forma balance sheet attached as Exhibit 99.1, the trust account holding increased to $115,490,807, which reflects principal from 11,500,000 public shares designated at a redemption value of $10.00 per share plus $490,807 in interest earned on trust investments that was formally transferred to ordinary shares subject to possible redemption. The document does not modify the existing redemption calendar or trigger any extension provisions. Why it matters: This filing locks in the final post-IPO capitalization mechanics, fixing the public float at 11,500,000 shares and defining the exact cash reservoir available for shareholder redemptions or business combination financing. The pro forma statements detail specific operational cash movements incurred since the IPO: $38,285 in deferred offering costs reallocated from deferred assets to additional paid-in capital, $22,642 in paid professional fees, $7,500 in paid audit fees, $8,000 in accrued legal fees, and $6,000 in advanced trust management fees. Chief Executive Officer and Chief Financial Officer Shaoren Liu executed the report on April 21, 2026, identifying the registrant as a Cayman Islands emerging growth company with principal executive offices at 13501 Katy Fwy Houston, TX 77079 and securities listed on the New York Stock Exchange under symbols TRAD, TRADU, and TRADR.

What changed: Form 10-Q (Quarterly Report pursuant to Section 13 or 15(d) of the Exchange Act) for the quarterly period ended February 28, 2026, filed by APEX Tech Acquisition Inc. (TRAD). First quarterly report since the company's IPO on Feb 27, 2026. The company went from pre-IPO shell (zero trust, zero cash) to having $111.97M in trust, $584k working capital, and current liabilities extinguished. The IPO closed at $10.00/unit (including partial overallotment); sponsor purchased 208,971 private units for $2.09M. Management discloses 'substantial doubt' about going concern if a deal is not consummated within 15 months (by May 2027). Why it matters: This is the first public look at TRAD's freshly-funded balance sheet. Trust is $10.06/share on 11,197,131 public shares. The 15-month deadline is May 25, 2027. No target has been identified. The sponsor (APEX INNOVATION ACQUISITION CORP.) owns 2.8M founder shares at an extraordinarily low cost basis (~$0.009/share), creating a massive incentive to close a deal. The auditor going-concern language raises the stakes; shareholders should track deal announcements closely.

What changed: Joint Filing Agreement (Exhibit 99.1) attached to a Schedule 13D, confirming that Apex Innovation Acquisition Corp. and Director Shaoren Liu will jointly file the beneficial ownership report and all future amendments pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934. The undersigned parties formally established a procedural conduit for coordinated disclosure of beneficial ownership in ordinary shares with a par value of $0.0001 per share in a Cayman Islands entity. The filing contains no amendments to trust distribution schedules, redemption floor prices, extension vote procedures, or business combination timelines. Sponsor conduct beyond executing a joint filing protocol remains undocumented, and the issuer’s operational status continues to reflect the externally tracked SEARCHING phase without modification from this text. Why it matters: For investors monitoring redemption liquidity and sponsor commitment, the agreement signals administrative alignment between a sponsor vehicle and a director but delivers zero incremental data on deal progress or capital preservation. The undersigned parties made no representations regarding target industry sizing, projected customer contracts, technology integration roadmaps, partnership term sheets, pending litigation, or executive retention metrics. Consequently, the document preserves the existing framework for trust accounting and holder voting rights without advancing the execution calendar or altering the mechanics governing shareholder redemptions.

What changed: A Form 8-K Current Report confirming the consummation of an initial public offering and the establishment of a shareholder trust account. In its filing dated March 6, 2026, APEX Tech Acquisition Inc. reports the February 27, 2026 closing of 11,197,131 public units at $10.00 each, yielding $111,971,310 in gross proceeds, which includes a partial over-allotment exercise of 1,197,131 units. Simultaneously, Sponsor APEX INNOVATION ACQUISITION CORP. bought 208,971 private units at $10.00 apiece for $2,089,710. The Company deposited $111,971,310 into the trust account. Management states the 15-month combination window expires on May 27, 2027, assuming no extensions. The sponsor conducts its standard SPAC obligations: waiving redemption rights on founder and private shares, agreeing to vote in favor of deals, and accepting liability to replenish the trust if third-party claims drop it below $10.00 per share. Rights attached to units expire worthless if liquidated. The Company retains $584,080 outside the trust for operations. Why it matters: This filing finalizes the mechanical parameters for TRAD holders, locking the initial redemption pool at $111,971,310 across 11,197,131 public shares and setting the May 27, 2027 hard stop for redemptions or acquisitions. The sponsor’s indemnity obligation and the 80% trust-balance screening requirement for targets establish the baseline protection and deal velocity expectations. Auditors Simon & Edward, LLP explicitly flagged a going concern due to mandatory liquidation risk, underscoring that the $584,080 operating reserve is tightly drawn against professional costs. Beyond mechanics, Chief Executive Officer Shaoren Liu signed off on zero-current operations, unlimited industry/region target search criteria, and upfront risks surrounding U.S.-China trade tensions and global conflicts. The underwriter secured a $1,119,713 fee, 50,000 immediate representative shares, and a commitment for 223,943 deferred shares, while granting A.G.P. a 12-month right of first refusal for future financings.